Virpax Pharmaceuticals VRPX

$ 0.69 -5.08%

Quarterly report 2024-Q2
added 08-12-2024

Virpax Pharmaceuticals Balance Sheet 2011-2024 | VRPX

Annual Balance Sheet Virpax Pharmaceuticals

	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
Net Debt	-	-	-	489 K	1.22 M	452 K	-	-	-	-	-	-	-
Long Term Debt	-	-	-	-	-	-	-	-	-	-	-	-	-
Long Term Debt Current	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Non Current Liabilities	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Current Liabilities	7.69 M	3.09 M	2.09 M	-	-	-	-	-	-	-	-	-	-
Total Liabilities	7.69 M	3.09 M	2.09 M	1.02 M	2.78 M	1.25 M	-	-	-	-	-	-	-
Deferred Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-
Retained Earnings	-59.5 M	-44.4 M	-22.7 M	-	-6.31 M	-3 M	-	-	-	-	-	-	-
Total Assets	9.63 M	19.7 M	39.6 M	465 K	46.7 K	61.5 K	-	-	-	-	-	-	-
Cash and Cash Equivalents	9.14 M	19 M	36.8 M	54.8 K	-	-	-	-	-	-	-	-	-
Book Value	1.93 M	16.6 M	37.5 M	-556 K	-2.73 M	-1.19 M	-	-	-	-	-	-	-
Total Shareholders Equity	1.93 M	16.6 M	37.5 M	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency

Quarterly Balance Sheet Virpax Pharmaceuticals

	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
Long Term Debt	-	-	-	-	-	-	-	-	-	-	-	-	1.07 M	1.07 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Non Current Liabilities	-	-	-	-	-	-	-	-	-	-	-	-	1.02 M	1.02 M	1.02 M	-	1.02 M	1.02 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Liabilities	5.39 M	4.34 M	7.69 M	6.53 M	3.65 M	3.29 M	3.09 M	4.21 M	2.48 M	2.19 M	2.09 M	1.81 M	3.85 M	3.66 M	4.68 M	4.68 M	4.68 M	4.68 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Deferred Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Retained Earnings	-66.2 M	-62.8 M	-59.5 M	-55 M	-49 M	-45.9 M	-44.4 M	-41.4 M	-33.7 M	-27.8 M	-22.7 M	-18.6 M	-15.4 M	-13 M	-10.6 M	-10.6 M	-10.6 M	-10.6 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Assets	2.59 M	3.13 M	9.63 M	13 M	16 M	18.5 M	19.7 M	23.6 M	29.4 M	34.7 M	39.6 M	43.3 M	11.4 M	13.2 M	465 K	465 K	465 K	465 K	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Cash and Cash Equivalents	1.87 M	1.87 M	9.14 M	12.2 M	14.8 M	17 M	19 M	20.6 M	26.1 M	30.8 M	36.8 M	41.7 M	10.5 M	12.3 M	54.8 K	257 K	54.8 K	54.8 K	41.5 K	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Book Value	-2.79 M	-1.21 M	1.93 M	6.51 M	12.3 M	15.2 M	16.6 M	19.4 M	26.9 M	32.6 M	37.5 M	41.5 M	7.54 M	9.56 M	-4.22 M	-4.22 M	-4.22 M	-4.22 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Shareholders Equity	-2.79 M	-1.21 M	1.93 M	6.51 M	12.3 M	15.2 M	16.6 M	19.4 M	26.9 M	32.6 M	37.5 M	41.5 M	7.54 M	9.56 M	-4.22 M	-4.22 M	-4.22 M	-4.22 M	-2.73 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency